https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]> Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26254 Sat 24 Mar 2018 07:40:18 AEDT ]]> All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25283 Sat 24 Mar 2018 07:38:13 AEDT ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51900 Fri 22 Sep 2023 09:29:58 AEST ]]>